[1] |
Janes SM, Alrifai D, Fennell DA.Perspectives on the treatment of malignant pleural mesothelioma[J]. N Engl J Med, 2021, 385: 1207-1218.
|
[2] |
Wang Y, Jiang Z, Yan J, et al. HMGB1 as a potential biomarker and therapeutic target for malignant mesothelioma[J]. Dis Markers, 2019, 2019:4183157.doi:10.1155/2019/4183157.
|
[3] |
Nicholson AG, Sauter JL, Nowak AK, et al. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach[J]. J Thorac Oncol, 2020, 15: 29-49.
|
[4] |
Yu K, Proost P.Insights into peptidylarginine deiminase expression and citrullination pathways[J]. Trends Cell Biol, 2022, 32: 746-761.
|
[5] |
Chavanas S, Mechin MC, Takahara H, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6[J]. Gene, 2004, 330:19-27.
|
[6] |
Wang Y, Chen R, Gan Y, et al. The roles of PAD2- and PAD4-mediated protein citrullination catalysis in cancers[J]. Int J Cancer, 2021, 148: 267-276.
|
[7] |
Zheng L, Nagar M, Maurais AJ, et al. Calcium regulates the nuclear localization of protein arginine deiminase 2[J]. Biochemistry, 2019, 58: 3042-3056.
|
[8] |
Li F, Miao L, Xue T, et al. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells[J]. J Exp Clin Cancer Res, 2019, 38: 414.doi:10.1186/s13046-019-1404-8.
|
[9] |
闫晓俊, 徐文彬, 王冬来. 羧基末端乙酰化修饰调控抑癌蛋白p53转录特异性[J]. 基础医学与临床, 2021, 41: 1577-1582.
|
[10] |
Shi L, Yao H, Liu Z, et al. Endogenous PAD4 in breast cancer cells mediates cancer extracellular chromatin network formation and promotes lung metastasis[J]. Mol Cancer Res, 2020, 18: 735-747.
|
[11] |
Zhu D, Zhang Y, Wang S.Histone citrullination: a new target for tumors[J]. Mol Cancer, 2021, 20: 90.doi:10.1186/s12943-021-01373-z.
|